114 related articles for article (PubMed ID: 8535319)
1. Evidence for a possible role of Asialo-GM1-positive cells in the graft-versus-leukemia repression of a murine type-C retroviral leukemia.
OKunewick JP; Kociban DL; Machen LL; Buffo MJ
Bone Marrow Transplant; 1995 Sep; 16(3):451-6. PubMed ID: 8535319
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the effects of CD3 and CD5 donor T cell depletion on graft-versus-leukemia in a murine model for MHC-matched unrelated-donor transplantation.
Okunewick JP; Kociban DL; Machen LL; Buffo MJ
Bone Marrow Transplant; 1994 Jan; 13(1):11-7. PubMed ID: 7517254
[TBL] [Abstract][Full Text] [Related]
3. The role of CD4 and CD8 T cells in the graft-versus-leukemia response in Rauscher murine leukemia.
OKunewick JP; Kociban DL; Machen LL; Buffo MJ
Bone Marrow Transplant; 1991 Dec; 8(6):445-52. PubMed ID: 1686416
[TBL] [Abstract][Full Text] [Related]
4. The role of antibodies to IL-2 receptor and Asialo GM1 on graft-versus-leukemia effects induced by bone marrow allografts in murine B cell leukemia.
Weiss L; Reich S; Slavin S
Bone Marrow Transplant; 1995 Sep; 16(3):457-61. PubMed ID: 8535320
[TBL] [Abstract][Full Text] [Related]
5. A subset of asialo GM1+ cells play a protective role in the occurrence of graft-versus-host disease in mice.
De Ruysscher D; Sobis H; Vandeputte M; Waer M
J Immunol; 1991 Jun; 146(12):4065-70. PubMed ID: 1828259
[TBL] [Abstract][Full Text] [Related]
6. Graft-vs-leukemia and moderation of graft-vs-host reaction in transplantation therapy of viral leukemia.
Okunewick JP; Meredith RF; Raikow RB; Brozovich BJ; Magliere K
Exp Hematol; 1981 Aug; 9(7):754-65. PubMed ID: 7032959
[TBL] [Abstract][Full Text] [Related]
7. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
Johnson BD; Becker EE; Truitt RL
Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
[TBL] [Abstract][Full Text] [Related]
8. Prevention of lethal, minor-determinate graft-host disease in mice by the in vivo administration of anti-asialo GM1.
Charley MR; Mikhael A; Bennett M; Gilliam JN; Sontheimer RD
J Immunol; 1983 Nov; 131(5):2101-3. PubMed ID: 6355291
[TBL] [Abstract][Full Text] [Related]
9. Abrogation of graft-vs.-leukemia activity after depletion of CD3+ T cells in a murine model of MHC-matched peripheral blood progenitor cell transplantation (PBPCT).
Uharek L; Glass B; Zeis M; Dreger P; Steinmann J; Löffler H; Schmitz N
Exp Hematol; 1998 Feb; 26(2):93-9. PubMed ID: 9472798
[TBL] [Abstract][Full Text] [Related]
10. Graft-versus-leukemia effect in allogeneic bone marrow transplantation in mice against several radiation-induced leukemias.
Aizawa S; Sado T; Kamisaku H; Nemoto K; Yoshida K
Bone Marrow Transplant; 1994 Feb; 13(2):109-14. PubMed ID: 8205078
[TBL] [Abstract][Full Text] [Related]
11. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease.
Fowler DH; Breglio J; Nagel G; Eckhaus MA; Gress RE
J Immunol; 1996 Dec; 157(11):4811-21. PubMed ID: 8943383
[TBL] [Abstract][Full Text] [Related]
12. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
[TBL] [Abstract][Full Text] [Related]
13. Natural killer cells as effector cells of graft-versus-leukemia activity in a murine transplantation model.
Uharek L; Glass B; Gaska T; Zeiss M; Gassmann W; Löffler H; Müller-Ruchholtz W
Bone Marrow Transplant; 1993; 12 Suppl 3():S57-60. PubMed ID: 8124260
[TBL] [Abstract][Full Text] [Related]
14. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
Strober S
Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
[TBL] [Abstract][Full Text] [Related]
15. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
[TBL] [Abstract][Full Text] [Related]
16. Natural killer (NK) cells and graft-versus-host disease (GVHD): no correlation between the NK cell levels and GVHD in the murine P----F1 model.
Varkila K; Hurme M
Immunology; 1985 Jan; 54(1):121-6. PubMed ID: 3972429
[TBL] [Abstract][Full Text] [Related]
17. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
Jones SC; Murphy GF; Korngold R
Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
[TBL] [Abstract][Full Text] [Related]
18. Depletion of asialo-GM1+ cells from the F1 recipient mice prior to irradiation and transfusion of parental spleen cells prevents mortality to acute graft-versus-host disease and induction of anti-host specific cytotoxic T cells.
Varkila K
Clin Exp Immunol; 1987 Sep; 69(3):652-9. PubMed ID: 3499271
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapeutic aspects of allogeneic peripheral progenitor cells.
Glass B; Uharek L; Hartung G; Zeis M; Steinmann J; Dreger P; Krönke M; Schmitz N
Bone Marrow Transplant; 1998 Jun; 21 Suppl 3():S3-8. PubMed ID: 9712483
[TBL] [Abstract][Full Text] [Related]
20. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.
Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B
Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
